產(chǎn)品名稱： NCI-H2030人非小細(xì)胞肺癌細(xì)胞、 NCI-H2030人非小細(xì)胞肺癌細(xì)胞、 NCI-H2030人非小細(xì)胞肺癌細(xì)胞、 NCI-H2030人非小細(xì)胞肺癌細(xì)胞；

their immune contexture may allow biology driven design of novel immune modulating or immune targeting therapies.Clinical issue: Hepatocellular carcinoma (HCC) is associated with a high mortality rate.
Standard treatment: For many years, sorafenib was the only, and frequently poorly tolerated